Our Services
We provide services tailored to your needs
InterpretBIO brings the experience, knowledge and network of appropriate stakeholders together to drive successful go-to-market strategies, curation services, software solutions, and more.
Precision Medicine Evaluation and Marketing Services
We provide services for assessing a product's fit to market through Voice of Customer (VOC), market analysis, and Key Opinion Leader (KOL) engagements.
Product to
Market Fit
Voice of Customer Insights
Company Partnership
Development
Market
Strategy
Tactical Marketing Campaigns
Key Opinion Leader Engagement
Assay Development and Knowledge Base
We provide guidance for assay development, and up-to-date curation and knowledge base services.
Assay Development Support
-
For molecular diagnostic and life science companies, we provide guidance on biomarkers by tumor type.
-
For example, in non-small cell lung cancer (NSCLC), the most recurrently altered druggable genes include EGFR, KRAS, MET, ALK, and ROS. Panel based testing for NSCLC must include these genes. However, if the goal is to capture other clinically relevant targets, a larger panel may be the solution, which may help to identify additional targets for therapies, trials or immunotherapy.
For a complete list of Biomarkers associated with Tumor-types and approved targeted therapies contact us.
Curation, Knowledge Base and Clinical Reporting Services and Consultation
-
We provide our clients with variant prioritization services based on annotations including, but not limited to variant allele occurrence, presence in population variant database and cancer variant databases, and strong evidence from functional characterization. This helps us advise our clients on how to create the most comprehensive clinical reports.
-
We also provide our clients with information on variant tiers based on FDA approved biomarkers of targeted therapies, professional guidelines (ASCO, NCCN, AMP) and clinical studies for clinical reporting.
Clinical Curation Process
At a high level, clinical curation of tumor variants involve evaluating somatic alterations of interest. Variant prioritization is based on professional guidelines, several database annotations and functional evidences and precision clinical trials.
Example 1
Tumor Type | Biomarker | Targeted Therapies | Response | On-Label | Tier |
|---|---|---|---|---|---|
NSCLC | EGFR L858R | Erlotinib (TARCEVA),
Gefitinib (IRESSA),
Afatinib (GILOTRIF),
Osimertinib (TAGRISSO), Ramucirumab (CYRAMZA),
Dacomitinib (VIZIMPRO) | Sensitive | Yes | 1 |
NSCLC | MET exon 14 skipping (METex14) | Capmatinib (TABRECTA),
Tepotinib (TEPMETKO)
| Sensitive | Yes | 1 |
Example 2
Tumor Type | Biomarker | Targeted Therapies | Response | On-Label | Tier |
|---|---|---|---|---|---|
Cholangiocarcinoma | FGFR2-KIAA1598 fusion* | Pemigatinib (PEMAZYRE) | Sensitive | Yes | 1 |
Erdafitinib (BALVERSA) | Sensitive | No | 1 |
*Note: Actionability is based on fusion breakpoints, and the presence of kinase domain sequence in the fusion.
Example 3
Tumor Type | Biomarker | Targeted Therapies | Response | On-Label | Tier |
|---|---|---|---|---|---|
Pilocytic astrocytoma | KIAA1549-BRAF fusion* | Vemurafenib (ZELBORAF),
Dabrafenib (TAFINLAR) | Resistance | No | - |
Pilocytic astrocytoma | KIAA1549-BRAF fusion* | Trametinib (MEKINIST), Selumetinib (KOSELUGO) | Partial Response | No | 2 |
*Note: Actionability is based on fusion breakpoints, and the presence of kinase domain sequence in the fusion.
Example 4
Tumor Type | Biomarker | Targeted Therapies | Response | On-Label | Tier |
|---|---|---|---|---|---|
MASC (Mammary analogue secretory carcinoma) | ETV6-NTRK3 fusion* | Larotrectinib (VITRAKVI), Entrectinib (ROZLYTREK) | Sensitive | Yes | 1 |
MASC | NTRK3 G623R | Larotrectinib (VITRAKVI), Entrectinib (ROZLYTREK) | Resistance | - | 1 |
*Note: Actionability is based on NTRK3 breakpoints, and the presence of kinase domain sequence in the fusion.
Example 5
Tumor Type | Biomarker | Targeted Therapies | Response | On-Label | Tier |
|---|---|---|---|---|---|
AML | FLT3-ITD | Gilteritinib (XOSPATA) | Sensitive | Yes | 1 |
Example 6
Tumor Type | Biomarker | Prognosis |
|---|---|---|
AML | NPM1 mut | Favorable
|
AML | NPM1 mut + FLT3-ITD | Unfavorable
(In patients < 60 y) |
Software
Development
Services
-
FHIR
-
SMART on FHIR
-
ETL
-
Cloud
-
Data Analytics and Insights